AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1474771
Drug: Intraperitoneal neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal neostigmine (2 mg)
Trial: 22877811
Drug: Percutaneous Coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous Coronary Intervention + Optimal Medical Therapy (PCI + OMT)
Trial: 20528213
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg suppositories
Trial: 20528213
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablets
Trial: 16422810
Drug: Vardenafil (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (5-20 mg)
Trial: 500834
Drug: Calcium ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium ingestion (0.0, 0.5, 1.5, and 3.0 g of elemental calcium as gluconate)
Trial: 31538444
Drug: Decontaminant material
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decontaminant material (sulfonic/sulphuric acid solution, HybenX, EPIEN Medical)
Trial: 9929017
Drug: leflunomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide (100 mg daily on days 1-3, then 20 mg daily)
Trial: 9929017
Drug: sulphasalazine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphasalazine (0.5 g daily, titrated to 2.0 g daily at week 4)
Trial: 7486098
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 mg/mL (0.1%)
Trial: 7486098
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg/mL (0.2%)
Trial: 7486098
Drug: Ropivacaine 3
RxNorm normalized name: fentanyl-ropivacaine 3 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3 mg/mL (0.3%)
Trial: 7486098
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/mL (0.25%)
Trial: 11388526
Drug: Ropivacaine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (various doses)
Trial: 7486098
Drug: Bupivacaine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (2.5 mg/mL)
Trial: 2354484
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg thrice daily
Trial: 466753
Drug: Intravenous 20
RxNorm normalized name: Dantrium Intravenous 20mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 20 micrograms NAB 365 (clenbuterol)
Trial: 466753
Drug: Intravenous 250
RxNorm normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 250 micrograms terbutaline
Trial: 29801515
Drug: DC vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC vaccination as an add-on to the standard therapy
Trial: 29801515
Drug: Standard radio/temozolomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radio/temozolomide chemotherapy
Trial: 23911183
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy (control)
Trial: 15336297
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) 20 mg
Trial: 21077572
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine (IMI) 75 mg
Trial: 18518892
Drug: Sitagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg once daily for moderate renal insufficiency; 25 mg once daily for severe renal insufficiency)
Trial: 18518892
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by glipizide (2.5 or 5 mg/day, uptitrated to max 20 mg/day)
Trial: 11828246
Drug: C (caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (caffeine 4 mg/kg)
Trial: 11828246
Drug: E (ephedrine
RxNorm normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (ephedrine 0.8 mg/kg)
Trial: 11828246
Drug: C +
RxNorm normalized name: Probiotic + Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C + E (caffeine 4 mg/kg + ephedrine 0.8 mg/kg)
Trial: 11828246
Drug: E (ephedrine
RxNorm normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (ephedrine 0.8 mg/kg) and C + E
Trial: 8547834
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of retinol (25,000 IU) for 5 years in SKICAP-AK trial
Trial: 8547834
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of retinol (25,000 IU) or 13‐cis‐retinoic acid (5 or 10 mg) for 3 years in SKICAP-S/B trial
Trial: 2310247
Drug: Nicardipine cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine cardioplegia (0.25 mg/L)
Trial: 7003700
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus chemotherapy (RT+CT)
Trial: 28109295
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg qd
Trial: 28109295
Drug: glimepiride 1-4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride 1-4 mg qd
Trial: 6366148
Drug: Overall (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (both treatments)
Trial: 9332804
Drug: Professional tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional tooth cleaning and oral health education program (test)
Trial: 2646206
Drug: Roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 300 mg once a day
Trial: 8476960
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg day 1 and 100 mg day 2-10
Trial: 30683523
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (15mg/kg)
Trial: 18317788
Drug: Oral rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifampicin
Trial: 18317788
Drug: Submucosal placentrex
RxNorm normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Submucosal placentrex injection
Trial: 15741048
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (GT) - 2 cups containing approximately 250 mg of total catechins
Trial: 12512987
Drug: 5% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% carbamide peroxide bleaching gel + potassium nitrate in a custom tray (Colgate Platinum Gentle Plus)
Trial: 23272987
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy
Trial: 22905891
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg i.v. followed by paracetamol 2 g i.v. 30 min later
Trial: 22905891
Drug: Paracetamol 2
RxNorm normalized name: Paracetamol 24 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 2 g i.v.
Trial: 18367379
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with daily glutamine supplement of 0.35 g/kg
Trial: 18367379
Drug: Isocaloric‐isonitrogenous parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric‐isonitrogenous parenteral nutrition (Control)
Trial: 12633918
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg buprenorphine tablets sublingually for 10 days
Trial: 3440508
Drug: Alginate/antacid chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate/antacid chewing tablets and metoclopramide
Trial: 2486782
Drug: Overall tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall tolerance of triphasic preparation (LOGYNON)
Trial: 31952632
Drug: Xylazine (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (0.20 mg kg‐1)
Trial: 31952632
Drug: Dexmedetomidine (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.005 mg kg‐1)
Trial: 25091954
Drug: Brilliant blue
RxNorm normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brilliant blue G (BBG) under air infusion (group 1)
Trial: 25091954
Drug: Brilliant blue
RxNorm normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brilliant blue G (BBG) injected into the vitreous cavity (group 2)
Trial: 23021155
Drug: Mustard (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mustard (21 g)
Trial: 23021155
Drug: Horseradish (8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horseradish (8.3 g)
Trial: 23021155
Drug: Ginger (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (20 g)
Trial: 23021155
Drug: Black pepper
RxNorm normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black pepper (1.3 g)
Trial: 22036523
Drug: Lyprinol(®) 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyprinol(®) 200mg daily for 8 weeks
Trial: 19463379
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa antagonist
Trial: 19463379
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (no GP IIb/IIIa antagonist)
Trial: 11332869
Drug: propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (40 mg twice daily)
Trial: 9522971
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin administration by caregivers
Trial: 3508553
Drug: Etretinate 25
RxNorm normalized name: etretinate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate 25 mg
Trial: 3508553
Drug: Etretinate 50
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate 50 mg
Trial: 3508553
Drug: Etretinate 75
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate 75 mg
Trial: 3508553
Drug: Etretinate 100
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate 100 mg
Trial: 27067604
Drug: Module group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Module group (MG)
Trial: 2647494
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin plus dipyridamole
Trial: 12542565
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with transdermal 17‐beta oestradiol and medroxyprogesterone acetate
Trial: 12542565
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for CHD
Trial: 11505388
Drug: 2 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of the same chemotherapy after 6 cycles of induction chemotherapy
Trial: 11505388
Drug: (sub)total lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (sub)total lymph node irradiation after 6 cycles of induction chemotherapy
Trial: 9248317
Drug: Formoterol (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (long-acting beta 2-agonist)
Trial: 8256188
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and mezlocillin (gentamicin 1.0 to 1.5 mg/kg every 8 hours; mezlocillin 3 to 4 grams every 4 to 6 hours)
Trial: 31370128
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral prednisolone twice daily for four days
Trial: 28882536
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 on day 1 every 3 weeks
Trial: 28882536
Drug: Gemcitabine 675
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 675 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8 every 3 weeks
Trial: 17673814
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2, every 3 weeks)
Trial: 17673814
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2, every 3 weeks) + 5'DFUR (600 mg/body)
Trial: 15152060
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy plus a single-chamber ICD
Trial: 11332171
Drug: Beractant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beractant (100 mg kg-1) administered 2 hours after the first dose
Trial: 11332171
Drug: Beractant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beractant (100 mg kg-1) administered 6 hours after the first dose
Trial: 7846948
Drug: Oral digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin (0.125 mg three times daily up to 0.25 mg twice daily)
Trial: 7846948
Drug: Oral digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin (0.125 mg twice daily) and quinidine hydrogen sulphate (750‐1000 mg daily)
Trial: 7846948
Drug: Oral digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral digoxin (0.125 mg three times daily) and flecainide (200‐300 mg daily)
Trial: 9224961
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifabutin (300 mg once daily on days 16-30)
Trial: 9164416
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine mesylate (400 mg every 8 hours for 30 days)
Trial: 7737957
Drug: Fluoxetine (antidepressant)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (antidepressant) for 12 weeks
Trial: 2183734
Drug: Forced diuresis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced diuresis, chemotherapy, and plasmapheresis (group 2)
Trial: 2183734
Drug: Forced diuresis
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced diuresis and chemotherapy (group 1)
Trial: 457316
Drug: Topical salicylic
RxNorm normalized name: salicylic acid Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical salicylic acid in hydrophilic ointment applied to skin with removed stratum corneum
Trial: 457316
Drug: Topical salicylic
RxNorm normalized name: salicylic acid Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical salicylic acid in hydrophilic ointment applied to intact skin
Trial: 457316
Drug: Topical salicylic
RxNorm normalized name: salicylic acid Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical salicylic acid in polyethylene glycol 400 vehicle
Trial: 28591240
Drug: Sealant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealant treatment (n = 28)
Trial: 28591240
Drug: Restorative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorative treatment (n = 26)
Trial: 24843061
Drug: Follow-up formula
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up formula (FUF) with 25 mg DHA, 1.2 g PDX/GOS, and 8.7 mg yeast β‐glucan per serving, 3 servings per day for 28 weeks
Trial: 22773430
Drug: Acebron™ 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebron™ 4 mg (Test)
Trial: 22773430
Drug: Neo‐Sintrom™ 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo‐Sintrom™ 4 mg (Reference)
Trial: 8683518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of %WL, BMI, and MAMC
Trial: 1522190
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone 12.5 mg q.d. starting from the day after the HCG trigger, increased to 25 mg q.d. on the day of embryo transfer
Trial: 6347232
Drug: Aspirin (0.3-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (0.3-1.2 g single dose)
Trial: 6347232
Drug: Other nonsteroidal
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other nonsteroidal anti-inflammatory drugs (oral challenge)
Trial: 10399795
Drug: Glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid therapy
Trial: 25867415
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine A (CsA) alone
Trial: 25867415
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-dose hormone and low-dose CsA
Trial: 26864236
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic therapy
Trial: 26864236
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic therapy
Trial: 14966097
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg i.v. before chemotherapy plus 4 mg orally every 6 hours for four doses (arm A)
Trial: 14966097
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg i.v. single dose before chemotherapy (arm B)
Trial: 14966097
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg i.v. single dose before chemotherapy (arm C)
Trial: 11337977
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 3.9 g daily for 63 days
Trial: 29544472
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) - 2 g 2 hours before incision, 1 g at 6 and 12 hours after surgery
Trial: 29544472
Drug: Intra-articular tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular tranexamic acid (TXA) - 3 g in 100 mL of saline solution
Trial: 20113305
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus waiting list for DBT (TAU+WL)
Trial: 12847484
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to kitchen Bla g 1 levels greater than 1 U/g
Trial: 9001834
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg administered at bedtime
Trial: 2870754
Drug: Active trial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active trial or standard medication
Trial: 26856220
Drug: General hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General hydration (control group) with <500 mL normal saline at a normal rate (0.5 or 1 mL/kg.h)
Trial: 22873210
Drug: Interactive neurostimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive neurostimulation (INS) therapy
Trial: 22197956
Drug: Low-frequency force
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency force steadiness practice in plantar flexor muscles (5 sets of 60-s contraction at 10% and 20% MVC, once or twice a week for 4 weeks)
Trial: 16809568
Drug: ADMA (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADMA (0.10 mg ADMA/kg per min)
Trial: 12780424
Drug: Advice plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice plus iron supplement (60 mg Fe2+ - Ferromax)
Trial: 12780424
Drug: Advice plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+ - Hemofer)
Trial: 9360504
Drug: 17 beta-estradiol
RxNorm normalized name: 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (2.5 mg)